36% Scalp Hair Loss Prompts JAK Inhibitor for Alopecia Areata

A 29-year-old woman’s patchy scalp hair loss increased from 21% to 36% over three months, a 15-percentage-point rise in alopecia areata. Labeled Case 2, this single-patient discussion—not a cohort or comparative treatment study—centered on Dr. Ungar’s decision to classify the presentation as severe and start a JAK inhibitor.

The patient had no eyebrow, eyelash, or nail involvement and no reported autoimmune or atopic history. Topical corticosteroids and rosemary oil had provided little help.

Her scalp loss had progressed while she began avoiding social events and covering her head at work. Dr. Ungar said progression over about three months is common, but the defining feature here was anxiety interfering with work, productivity, and social life. He viewed that impairment as more consequential than scalp coverage alone.

Why did 36% hair loss qualify as severe?

On SALT alone, 36% scalp hair loss would appear moderate, Dr. Ungar said. He then weighed significant progression and psychosocial burden within the alopecia areata assessment and graded the presentation as severe. He described it as a clear-cut severe case in which psychosocial impact plays a core role.

The percentage therefore did not settle the assessment on its own. The patient was withdrawing from social events, and her fear of additional loss affected her functioning even with a covering available. Dr. Ungar addressed the view that this was only hair: “The effect on her life is huge.”

The two severity signals reinforced each other. The 15-point rise supplied evidence of ongoing activity, while withdrawal, head covering and anxiety showed the disease’s effect on daily life. A moderate percentage classification could coexist with severe functional impairment, and fear of continued loss added to the case for systemic treatment.

She also feared further progression, which Dr. Ungar said can occur. Her concern had a measured basis: scalp hair loss rose from 21% to 36% within three months. Rapid change and social withdrawal supplied the context for severe disease.

Why did the case warrant systemic treatment?

Ideally, Dr. Ungar said, management should combine medical therapy with multidisciplinary psychosocial care. That support includes therapists, social support, and support groups. The approach addresses anxiety that already disrupts work, productivity, and social participation rather than treating hair count as the only outcome.

Helping the patient regrow her hair was one of the most powerful available interventions, and regrowth requires medical therapy. Dr. Ungar said patients who regain hair often “feel like themselves again, almost like new people,” although some fear of relapse can persist. The benefit of regrowth was therefore a major reason to escalate to systemic therapy.

Regrowth may not end the clinical and social burden. Fear of relapse can persist after hair returns, which supports continued treatment and follow-up. His plan therefore combined immediate systemic disease control with longer-term support for anxiety, social participation and work productivity.

Staying on treatment also lowers the likelihood of worsening and later flares. Dr. Ungar concluded with a decision to start a JAK inhibitor because of both the rate of progression and the psychosocial burden. The segment names no specific inhibitor and reports no follow-up efficacy result; its endpoint is the treatment decision.

How will treatment success be judged?

The next episode, “Alopecia Areata Patient-Reported Outcomes: Defining Treatment Success and Monitoring Response,” will feature Dr. Ungar reviewing patient satisfaction data and timelines for assessing response. That discussion will extend the current case beyond severity, escalation and the JAK-inhibitor decision toward patient-reported outcomes and time points used to monitor benefit.